Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + fluorouracil + cisplatin
- Development stage
- Phase 2
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Doxorubicin + fluorouracil + cisplatin is a chemotherapy combination regimen used to treat various cancers, particularly gastrointestinal malignancies. This combination has been studied in gastric cancer, pancreatic cancer, and other upper gastrointestinal carcinomas. The regimen typically consists of cisplatin administered intravenously on day 1, doxorubicin administered intravenously on days 1 and 2, and 5-fluorouracil administered intravenously on day 2. In some protocols, vincristine may be added to this combination (C5VD). The combination shows promising efficacy but can cause toxicities including leukopenia, stomatitis, diarrhea, nausea, vomiting, and alopecia.
- Other names
- FAPC5VDC-5VDC 5VD
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + fluorouracil + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + fluorouracil + cisplatin.